Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

Universities are waiting cautiously as the agency's unilateral plan to cut billions of research support dollars has already ...

Reduction-in-force notices went out Tuesday morning to employees across HHS. At FDA, OND director Peter Stein is departing as ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create ...

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...